Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

December 14, 2023

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

December 11, 2023

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

December 08, 2023

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.

December 07, 2023

Eytan M. Stein, MD, discusses the ongoing development and investigation of therapies targeting splicing mutations in hematologic malignancies.

December 04, 2023

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

December 01, 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

November 30, 2023

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

November 24, 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

November 24, 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

November 17, 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

November 17, 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

November 16, 2023

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

November 16, 2023

Komal Jhaveri, MD, FACP, discusses unmet needs for patients with breast cancer, as well as ways to address these needs through discussion and collaboration.

November 15, 2023

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

November 10, 2023

Howard I. Scher, MD, discusses the evolution of molecular testing mechanisms in patients with prostate cancer and highlights the importance of making patient-centered decisions based on test results.

November 10, 2023

Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.

November 10, 2023

Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.

November 10, 2023

The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.

November 10, 2023

Research has continued to focus on developing novel therapies and bringing new treatments to the sarcoma treatment paradigm.

November 10, 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.